Lipigon Pharmaceuticals AB (publ)

Lipigon Pharmaceuticals AB (publ), a company based in Umeå, Sweden, specializes in the development of therapeutic solutions for lipid-related disorders. Their innovative pipeline includes the Lipisense project, designed to address severe hypertriglyceridemia (SHTG) and familial chylomicronemia syndrome (FCS). Additionally, they are advancing a gene therapy program for lipodystrophy, a rare condition marked by atypical fat distribution throughout the body. Their work also extends to developing treatments for dyslipidemia, a general lipid imbalance, and an RNA drug candidate for acute respiratory distress syndrome (ARDS). In a strategic collaboration with HitGen Inc., Lipigon is also involved in creating small molecule therapies aimed at dyslipidemia, cardiovascular ailments, and other metabolic conditions. The firm, established in Umeå, Sweden, began its operations in 2010.